Indian Drugmakers Prepare for Next Generation GLP-1 Medications as Price Competition Fades

Indian Pharmaceutical Market to Witness Surge in GLP-1 Therapies

March 2026

The Indian pharmaceutical market is expected to experience a significant shift in the GLP-1 therapy landscape with the expiration of exclusivity for semaglutide in mid-March 2026. Over 50 generic brands are poised to enter the market, sparking an aggressive price war and triggering a transition from scarcity to abundance.

Market Opportunity and Growth

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

India offers a substantial market opportunity for GLP-1 therapies, with over 100 million people suffering from Type-2 Diabetes and 135 million estimated to be overweight or obese. The anti-diabetic therapy segment has already seen a 15.5% value growth in early 2026, driven by new product introductions. The arrival of affordable alternatives is expected to accelerate this trend, shifting the market from premium exclusivity to broad physician adoption.

Competition and Market Strategy

Industry analysts predict that new entrants will offer semaglutide at one-third to one-fifth of the innovator's cost. To navigate the crowded market, manufacturers are adopting ecosystem-led differentiation strategies, including introducing bundled packs, tiered pricing models, and support programs for long-term patient retention.

Key Players and Market Analysis

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Major Indian pharmaceutical companies, such as Dr. Reddy's Laboratories, Sun Pharma, Mankind Pharma, Lupin, Zydus Lifesciences, Alkem Laboratories, Intas Pharmaceuticals, and Eris Lifesciences, are gearing up to enter or scale their presence in the expanding GLP-1 segment. The market winners will be those who can provide a consistent and reliable supply, converting a crowded molecule into a trusted therapy experience.

Market Trends and Outlook

The competitive focus is shifting from initial prescriptions to long-term patient refills, driven by the need for ongoing management of semaglutide. The value-driven growth in the chronic segment will be accelerated by off-patent opportunities and the rising incidence of non-communicable diseases. Data from the Indian Pharmaceutical Market (IPM) and Pharmarack highlights the increasing momentum of semaglutide, with incremental consumption outpacing its rival, Eli Lilly's Tirzepatide (Mounjaro).